ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.52
-0.17%
US Tech 100
17,585.60
-0.15%
S&P 500
5,187.67
0.00%
US Dollar vs CAD
1.37295
0.01%
Bitcoin
61,731.08
0.89%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) News

ASND Ascendis Pharma AS

133.93
-2.05 (-1.51%)
May 08 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Ascendis Pharma AS ASND NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-2.05 -1.51% 133.93 16:48:44
Open Price Low Price High Price Close Price Previous Close
135.00 133.52 137.32 133.93 135.98
more quote information »

Recent News

Date Time Source Heading
5/02/202415:01GLOBEAscendis Pharma Reports First Quarter 2024 Financial Results
4/25/202415:46GLOBEAscendis Pharma to Report First Quarter 2024 Financial..
4/24/202407:30GLOBEUnited Kingdom’s MHRA Approves YORVIPATH®..
3/07/202410:31EDGAR2Form 144 - Report of proposed sale of securities
3/05/202420:39EDGAR2Form 144 - Report of proposed sale of securities
3/05/202407:14EDGAR2Form 144 - Report of proposed sale of securities
3/05/202407:04EDGAR2Form 144 - Report of proposed sale of securities
3/05/202406:37EDGAR2Form 144 - Report of proposed sale of securities
3/04/202414:17EDGAR2Form 144 - Report of proposed sale of securities
3/04/202414:07EDGAR2Form 144 - Report of proposed sale of securities
3/04/202413:54EDGAR2Form 144 - Report of proposed sale of securities
3/04/202413:36EDGAR2Form 144 - Report of proposed sale of securities
3/04/202407:30GLOBEAscendis Pharma to Participate in the Leerink Partners..
3/01/202410:00EDGAR2Form 144 - Report of proposed sale of securities
2/29/202416:13EDGAR2Form 144 - Report of proposed sale of securities
2/28/202415:49EDGAR2Form 144 - Report of proposed sale of securities
2/27/202416:45EDGAR2Form 144 - Report of proposed sale of securities
2/21/202414:17EDGAR2Form 144 - Report of proposed sale of securities
2/16/202416:16EDGAR2Form 144 - Report of proposed sale of securities
2/16/202416:15EDGAR2Form 144 - Report of proposed sale of securities
2/16/202416:14EDGAR2Form 144 - Report of proposed sale of securities
2/14/202415:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/14/202410:40EDGAR2Form 144 - Report of proposed sale of securities
2/14/202408:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/07/202415:15EDGAR2Form 20-F - Annual and transition report of foreign private..
2/07/202415:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/07/202415:01GLOBEAscendis Pharma Reports Fourth Quarter and Full Year 2023..
2/07/202407:30GLOBEAscendis Pharma to Participate in the Oppenheimer 34th..
1/31/202415:15GLOBEAscendis Pharma to Report Full Year 2023 Financial Results..
1/31/202415:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/31/202415:01GLOBEAscendis Pharma Launches 2nd TransCon™ Product: YORVIPATH®..
1/29/202407:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/29/202407:30GLOBENew Company Eyconis Formed to Develop Ascendis Pharma..
1/10/202415:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/08/202407:20GLOBEVector Pharma FZCO Announce Exclusive Distribution Agreement..
1/08/202405:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/08/202405:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/07/202416:45GLOBEAscendis Pharma Introduces Vision 2030
1/07/202413:00PRNUSSpecialised Therapeutics signs exclusive agreement with..
1/02/202405:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/28/202315:15GLOBEAscendis Pharma to Participate in the 42nd Annual J.P...
12/20/202307:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/20/202307:30GLOBESignificant Health and Quality of Life Improvements Achieved..
12/19/202315:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/19/202307:30GLOBETransCon™ hGH (lonapegsomatropin) Achieved Statistically..
12/13/202315:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/11/202307:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/11/202307:30GLOBEFDA Accepts for Review Resubmitted NDA for TransCon PTH..
12/07/202313:53EDGAR2Form 144 - Report of proposed sale of securities
12/05/202315:20EDGAR2Form 144 - Report of proposed sale of securities

Your Recent History

NASDAQ
ASND
Ascendis Pharma AS
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved